Fortschritte in Pathogenese und Therapie der Myasthenia gravis und des Lambert-Eaton-myasthenen Syndroms

Lernziele

Verständnis moderner pathogenetischer Grundlagen und Therapieprinzipien bei Myasthenia gravis und Lambert-Eaton-Syndrom.

Literatur

• 1 Besinger U A, Toyka K V, Homberg M. et al . Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.  Neurology. 1983;  33 1316-1321
• 2 Hohlfeld R, Melms A, Schneider C. et al . Therapy of myasthenia gravis and myasthenic syndromes. In: Brandt T, Caplan LR, Dichgans J, Diener H-C, Kennard C (eds) Neurological disorders - course and treatment. Amsterdam; Elsevier 2003: p 1341-1362
• 3 Toyka K V. Ptosis in myasthenia gravis: Extended fatigue and recovery bedside test.  Neurology. 2006;  67 1524
• 4 Toyka K V, Drachman D B, Pestronk A. et al . Myasthenia gravis: passive transfer from man to mouse.  Science. 1975;  190 397-399
• 5 Toyka K V, Drachman D B, Griffin D E. et al . Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.  N Engl J Med. 1977;  296 125-131
• 6 Hohlfeld R, Toyka K V. Therapies. In: Oosterhuis HJGH, de Baets M (eds) Myasthenia gravis. CRC Press, Inc 1993: 235-261
• 7 Marx A, Wilisch A, Schultz A. et al . Pathogenesis of myasthenia gravis.  Virchows Arch Int J Pathol. 1997;  430 355-364
• 8 Leite M I, Strobel P, Jones M. et al . Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.  Ann Neurol. 2005;  57 444-448
• 9 Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis.  Clin Immunol Immunopathol. 1977;  7 36-43
• 10 Toyka K V, Heininger K. [Acetylcholinrezeptor Antikörper bei der Diagnostik der Myasthenia gravis. Untersuchung von 406 Fällen].  Dtsch Med Wochenschr. 1986;  111 1435-1439
• 11 Pflughaupt K W, Becker T, Toyka K V. Azetylcholin-Rezeptor-Antikörper in der Diagnostik der Myasthenia gravis: stichprobenartige Erhebung zur Zuverlässigkeit des Doppelimmun-Präzipitationstests.  Akt Neurol. 1994;  21 63-65
• 12 Buchwald B, Ahangari R, Weishaupt A. et al . Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: Their neutralization by intravenous immunoglobulins.  Muscle & Nerve. 2005;  31 487-494
• 13 Hoch W, McConville J, Helms S. et al . Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.  Nat Med. 2001;  7 365-368
• 14 Vincent A, Bowen J, Newsom-Davis J. et al . Seronegative generalised myasthenia gravis: clinical features, antibodies and their targets.  Lancet Neurol. 2003;  2 99-106
• 15 Farrugia M E, Robson M D, Clover L. et al . MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.  Brain. 2006;  129 1481-1492
• 16 Heininger K, Hartung H-P, Toyka K V. et al . Therapeutic plasma exchange in myasthenia gravis: semiselective adsorption of Anti-AChR autoantibodies with tryptophane-linked polyvinylalcohol gels.  Ann N Y Acad Sci. 1987;  505 898-900
• 17 Gajdos P, Chevret S, Clair B. et al . Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis.  Ann Neurol. 1997;  41 789-796
• 18 Gajdos P, Tranchant C, Clair B. et al . Treatment of Myasthenia Gravis exacerbation with intravenous immunoglobulin - A randomized double-blind clinical trial.  Arch Neurol. 2005;  62 1689-1693
• 19 Flachenecker P, Taleghani B M, Gold R. et al . Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide.  Transfus Sci. 1998;  19, Suppl 43-46
• 20 Gold R, Toyka K V. Immuntherapie neurologischer Erkrankungen. Bremen; 2006
• 21 Schneider-Gold C, Hartung H P, Gold R. Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases.  Muscle & Nerve. 2006;  34 284-291
• 22 Drachman D B, Jones R J, Brodsky R A. Treatment of refractory myasthenia: „Rebooting” with high-dose cyclophosphamide.  Ann Neurol. 2003;  53 29-34
• 23 Chan A, Lee D H, Linker R. et al . Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease.  J Neurol. 2007;  254 1604-1606
• 24 Strobel P, Bauer A, Puppe B. et al . Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis.  J Clin Oncol. 2004;  22 1501-1509
• 25 Hohlfeld R, Toyka K V, Besinger U A. et al . Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine.  Ann Neurol. 1985;  17 238-242
• 26 Burns T M, Russell J A, LaChance D H. et al . Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome.  Ann Neurol. 2003;  53 270-273
• 27 Bain P G, Motomura M, Newsom-Davis J. et al . Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome.  Neurology. 1996;  47 678-683
• 28 Buchwald B, Weishaupt A, Toyka K V. et al . Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals.  Eur J Neurosci. 1998;  10 281-290
• 29 Buchwald B, Ahangari R, Weishaupt A. et al . Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome.  Ann Neurol. 2002;  51 673-680